It is well known that differences in patient medication response patterns may be partially explained by underlying genetic and biochemical disparities. The science of assessing how a patient’s genetics affect drug efficacy and safety is termed pharmacogenomics (also known as pharmacogenetics [PGx]). Utilizing PGx information may provide an important tool in diminishing the trial-and-error process in medication management. Genomind®, a unique personalized medicine platform that brings innovation to healthcare around the world, has designed a suite of products aimed to incorporate PGx into clinical decision-making when prescribing medications across multiple conditions. Genomind testing is conducted via a simple buccal swab and provides clinicians with insights regarding a patient’s likelihood for drug response and tolerability to particular drugs and combinations of drugs.